Background: Transcatheter closure of perimembranous ventricular septal defects in children is a highly effective procedure, but it can result in tricuspid regurgitation (TR). The associated risk factors and long-term outcomes of TR following the procedure are not well understood.
Methods And Results: This retrospective study included 1343 pediatric patients (age, 4.41±2.56 years) who underwent successful transcatheter perimembranous ventricular septal defect closure between 2002 and 2022, with a median follow-up of 78 (range, 12-244) months. TR was evaluated using echocardiography, and multivariate logistic regression was performed to identify independent risk factors of postprocedural TR. Postprocedural TR occurred in 12.1% of patients, including 143 new-onset cases and 20 with progressed preexisting TR. The majority of cases (86.5%) were mild, while 20 were moderate, and 2 were severe requiring surgical intervention. Most TR cases (84%) developed within 24 hours after the procedure. A higher right disc diameter-to-body weight ratio was identified as an independent risk factor of TR (odds ratio, 2.816 [95% CI, 1.315-6.032]). During follow-up, 71.8% of TR cases improved or resolved, though moderate TR persisted in 7 cases, and 1 progressed to severe TR requiring surgery 2 years after the procedure.
Conclusions: TR following perimembranous ventricular septal defect closure is common but typically mild and often resolves over time. A larger right disc diameter relative to body weight significantly increases the risk of TR, emphasizing the importance of careful device sizing, particularly in lighter patients. Long-term follow-up is crucial to detect potential late progression of TR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/JAHA.124.039443 | DOI Listing |
Rev Esp Cardiol (Engl Ed)
March 2025
Department of Pediatric Cardiology, SBU Tepecik Training and Research Hospital, Izmir, Turkey.
Introduction And Objectives: The Lifetech KONAR-MF ventricular septal defect occluder (MFO) is increasingly used for transcatheter perimembranous ventricular septal defect (pmVSD) closure. We aim to collect real-world data on patient outcomes and MFO performance in pmVSD cases.
Methods: This was a nonrandomized, retrospective, multicenter, postmarketing clinical follow-up study of pmVSD patients implanted with the MFO device between 2018 and 2023.
Background: Transcatheter closure of perimembranous ventricular septal defects in children is a highly effective procedure, but it can result in tricuspid regurgitation (TR). The associated risk factors and long-term outcomes of TR following the procedure are not well understood.
Methods And Results: This retrospective study included 1343 pediatric patients (age, 4.
Glob Cardiol Sci Pract
December 2024
Department of Comprehensive Heart Failure, Jefferson-Abington Hospital, PA, USA.
Iatrogenic ventricular septal defect (VSD) is a rare complication following transcatheter aortic valve implantation (TAVI). An 83-year-old male underwent TAVI for severe aortic stenosis (AS) and was diagnosed with a peri-membranous VSD on echocardiography, which was not evident on pre-procedural imaging. This case highlights the risk factors, symptoms, diagnosis, and management of iatrogenic VSD following TAVI.
View Article and Find Full Text PDFHeliyon
February 2025
Department of Pediatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
Background: This study evaluated left ventricular (LV) dimension changes after transcatheter ventricular septal defect (VSD) closure in children and identified factors influencing these changes.
Methods: We retrospectively studied 124 children (mean age: 3.5 ± 3.
Cardiol Young
February 2025
Pediatric Interventional Cardiology Department, Pediatric Specialties Hospital, Tuxtla GutiérrezChiapas, México.
Objectives: To demonstrate safety and efficacy of using the Amplatzer vascular plug II device for perimembranous ventricular septal defect closure with retrograde approach and show the follow-up in all patients.
Background: At present, there is no FDA-approved device for transcatheter closure of perimembranous ventricular septal defects. Small studies and case reports have shown the use of various catheter-based devices in an off-label management; however, there are no large studies to show their efficacy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!